Home
University of Bergen
Ingeborg Margrethe Bachmann's picture

Ingeborg Margrethe Bachmann

Department of Clinical Medicine
  • E-mailingeborg.bachmann@uib.no
  • Visitor Address
    Haukeland Universitetssykehus Laboratoriebygget, 7. etg. Heis øst
    5009 Bergen
  • Postal Address
    Postboks 7804
    5020 Bergen
Academic article
  • Show author(s) (2023). Expression of β-Catenin, E-Cadherin, and α-Smooth Muscle Actin in Basal Cell Carcinoma Before Photodynamic Therapy in Non-recurrent and Recurrent Tumors: Exploring the Ability of Predicting Photodynamic Therapy outcome. Journal of Histochemistry and Cytochemistry.
  • Show author(s) (2022). Basosquamous Basal Cell Carcinoma with Bone Marrow Metastasis. Current Oncology. 2193-2198.
  • Show author(s) (2019). Prognostic value of uPAR expression and angiogenesis in primary and metastatic melanoma. PLOS ONE. 1-18.
  • Show author(s) (2018). Secukinumab treatment in new-onset psoriasis: aiming to understand the potential for disease modification - rationale and design of the randomized, multicenter STEPIn study. Journal of the European Academy of Dermatology and Venereology. 1930-1939.
  • Show author(s) (2014). Nestin expression is associated with aggressive cutaneous melanoma of the nodular type. Modern Pathology. 396-401.
  • Show author(s) (2013). Melanoma prone families with CDK4 germline mutation: phenotypic profile and associations with MC1R variants. Journal of Medical Genetics. 264-U82.
  • Show author(s) (2012). Tumor necrosis is a prognostic factor in thick cutaneous melanoma. American Journal of Surgical Pathology. 1477-1482.
  • Show author(s) (2012). Suppression of heat shock protein 27 induces long-term dormancy in human breast cancer. Proceedings of the National Academy of Sciences of the United States of America. 8699-8704.
  • Show author(s) (2012). Prognostic Importance of the Mitotic Marker Phosphohistone H3 in Cutaneous Nodular Melanoma. Journal of Investigative Dermatology. 1247-1252.
  • Show author(s) (2010). Ki-67 expression is superior to mitotic count and novel proliferation markers PHH3, MCM4 and mitosin as a prognostic factor in thick cutaneous melanoma. BMC Cancer. 15 pages.
  • Show author(s) (2008). Tumor necrosis is associated with increased alphavbeta3 integrin expression and poor prognosis in nodular cutaneous melanomas. BMC Cancer. 362-372.
  • Show author(s) (2008). Mutation analysis of the EGFR-NRAS-BRAF pathway in melanomas from black Africans and other subgroups of cutaneous melanoma. Melanoma research. 29-35.
  • Show author(s) (2008). Loss of BMI-1 expression is associated with clinical progress of malignant melanoma. Modern Pathology. 583-590.
  • Show author(s) (2006). EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast. Journal of Clinical Oncology. 268-273.
  • Show author(s) (2005). Importance of P-cadherin, beta-catenin, and Wnt5a/frizzled for progression of melanocytic tumors and prognosis in cutaneous melanoma. Clinical Cancer Research. 8606-8614.
  • Show author(s) (2005). BRAF and NRAS mutations are frequent in nodular melanoma but are not associated with tumor cell proliferation or patient survival. Journal of Investigative Dermatology. 312-317.
  • Show author(s) (2004). Altered expression of cell cycle regulators Cyclin D1, p14, p16, CDK4 and Rb in nodular melanomas. International Journal of Oncology. 1559-1565.
Academic lecture
  • Show author(s) (2022). Clinical versus punch biopsy assessment of BCC subtype and thickness within a PDT-setting.
Letter to the editor
  • Show author(s) (2022). Toxic epidermal necrolysis after immune checkpoint inhibition, case report, and review of the literature. Acta Oncologica.
Doctoral dissertation
  • Show author(s) (2007). Biological Markers in Cutaneous Melanoma. A study with special focus on cell cycle regulation, cell adhesion proteins and tumor necrosis.
Abstract
  • Show author(s) (2022). How well do experienced dermatologists clinically assess basal cell carcinoma subtype and thickness before treatment with photodynamic therapy? . Acta Dermato-Venereologica. 43-43.
  • Show author(s) (2007). Loss of BMI-1 expression is associated with the clinical progress of malignant melanoma. Virchows Archiv. 452-452.
Poster
  • Show author(s) (2022). How well do experienced dermatologists clinically assess basal cell carcinoma subtype and thickness before treatment with photodynamic therapy? .
  • Show author(s) (2022). Clinical versus histological assessment of basal cell carcinoma for photodynamic therapy .
Academic literature review
  • Show author(s) (2013). Malignt melanom – diagnostikk, behandling og oppfølging i Norge. Tidsskrift for Den norske legeforening. 2154-2159.

More information in national current research information system (CRIStin)